Brainstorm Cell Cmn (BCLI) 2.42 $BCLI BrainStor
Post# of 273254
Posted On: 09/22/2016 7:02:25 AM
Brainstorm Cell Cmn (BCLI) 2.42 $BCLI
BrainStorm CEO to Present at Two Investor Conferences in September
PR Newswire - Tue Sep 06, 6:30AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at two upcoming investor conferences: The Rodman & Renshaw 18th Annual Global Investment Conference, and the Maxim Inaugural Israel Day.
BCLI: 2.42 (-0.10)
BrainStorm's Valuation Doesn't Reflect Potential Value of NurOwn(R) Therapy
ACCESSWIRE - Tue Aug 16, 7:01AM CDT
CHARLOTTE, NC / ACCESSWIRE / August 16, 2016 / BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease (PD). The company's NurOwn® technology is based on the use of mesenchymal stem cells (MSCs) that are engineered ex vivo to express increased amount of neurotrophic factors (NTFs). The company has tested single-dose treatments of NurOwn in ALS patients in two Phase 1/2 clinical trials and most recently in a randomized, double-blind, placebo-controlled Phase 2 clinical trial.
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu Aug 11, 7:00AM CDT
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2016.
BCLI: 2.42 (-0.10)
BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London
PR Newswire - Tue May 17, 7:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting Thursday, May 19th, at the 11th World Stem Cells & Regenerative Medicine Congress in London, UK. Mr. Lebovits will moderate a round table session on Brainstorm's NurOwn® proprietary technology and its potential to introduce a groundbreaking treatment for Amyotrophic lateral sclerosis (ALS).
BCLI: 2.42 (-0.10)
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief Scientist
PR Newswire - Thu May 12, 7:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1,470,000 from Israel's Office of the Chief Scientist (OCS).
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
PR Newswire - Tue May 10, 8:26AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2016.
BCLI: 2.42 (-0.10)
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 238.41 (-0.26), AVXL: 2.61 (-0.03), ACOR: 27.07 (+0.71), BCLI: 2.42 (-0.10), FOLD: 7.94 (+0.05)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 91.82 (+0.13), BMRN: 97.57 (-0.38), VYGR: 13.86 (+0.15), RPTP: 8.99 (+0.02), KNMD: (), SGMO: 4.72 (+0.10), BCLI: 2.42 (-0.10), CUR: 0.31 (unch)
Jama Neurology Releases Highly Promising Data From ALS Clinical Trial Conducted By Hadassah Medical Organization Jerusalem And Brainstorm Cell Therapeutics
PR Newswire Europe - Mon Jan 11, 6:21PM CST
ALS Clinical Trial Results Provide Strong Indication That Stem Cell Treatment Inhibits ALS Disease Progression In 87% of Patients
BCLI: 2.42 (-0.10)
BrainStorm's NurOwn® for the Treatment of ALS Published in JAMA Neurology
PR Newswire - Mon Jan 11, 9:45AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016 edition of JAMA Neurology discussing the outcome of the first in man Phase 1/2 study and Phase 2 dose escalation study with NurOwn® in ALS. The data provide indication of clinically meaningful benefit as reflected by a slower rate of disease progression in the period post treatment. There was also a positive trend on two novel biomarkers, rate of decline of muscle volume and of compound motor axon potential (CMAPs). These are the first published clinical data with stem cells that have been induced under culture conditions to produce NTFs, with the potential to achieve a neuroprotective effect in ALS and modify the course of disease.
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn® Trial in ALS at Hadassah Medical Center
PR Newswire - Mon Jan 11, 6:30AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with Hadassah Medical Center in Jerusalem, Israel, to conduct the planned multi dose Phase 2 trial with NurOwn® in Amyotrophic Lateral Sclerosis (ALS).
BCLI: 2.42 (-0.10)
BrainStorm Reschedules Corporate Update Conference Call to January 11, 2016
PR Newswire - Thu Dec 10, 6:45AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call, originally scheduled for Wednesday, December 16, 2015 to Monday, January 11, 2016, due to longer than expected embargo on one of the important items to be discussed on the call. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer will provide an update to shareholders and discuss important company developments.
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
PR Newswire - Mon Dec 07, 12:00AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Dr. Revital Geffen-Aricha, M.Sc., Ph.D., as Vice President of Research and Development. Dr. Geffen-Aricha will be based in Israel and report to Chaim Lebovits, President and Chief Executive Officer. She will be responsible for all research and development activities for BrainStorm.
BCLI: 2.42 (-0.10)
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Fri Dec 04, 8:00AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird"
in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.
ATHX: 1.97 (-0.01), IMUC: 0.12 (unch), BCLI: 2.42 (-0.10)
What's Driving the Price Movement - Research on HMN Financial, Metabolix, Brainstorm Cell Therapeutics and Milestone Scientific
ACCESSWIRE - Fri Dec 04, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / December 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: HMN Financial Inc. (NASDAQ: HMNF), Metabolix Inc. (NASDAQ: MBLX), Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) and Milestone Scientific Inc. (NYSE: MLSS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HMNF: 14.35 (unch), MLSS: 2.10 (+0.03), BCLI: 2.42 (-0.10), MBLX: 0.40 (+0.04)
BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
PR Newswire - Wed Dec 02, 8:10AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on Wednesday, December 16, 2015 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer will provide an update to shareholders and discuss important company developments.
BCLI: 2.42 (-0.10)
BrainStorm and Octane Biotech Announce Success in Cocoon(TM) Application Development Based on Customized Bioreactor for NurOwn® Stem Cells
PR Newswire - Tue Dec 01, 7:00AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian company that focuses on clinical systems for cell and tissue therapy, announced today that they have made significant progress toward the development of a novel bioreactor for industrial-scale manufacture of BrainStorm's NurOwn® neurotrophic-factor secreting mesenchymal stem cells. The companies have completed key development activities related to the customization of specific features of Octane's Cocoon(TM) instrumentation platform to enable efficient delivery of BrainStorm's NurOwn® stem cell therapy. The collaborative program has generated a NurOwn® therapy-specific cassette that is employed as a disposable cartridge within the standard Cocoon(TM) platform, along with a dedicated software program to deliver and track the NurOwn® process. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).
BCLI: 2.42 (-0.10)
BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist
PR Newswire - Mon Nov 30, 1:29AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant of approximately $735,000 from Israel's Office of the Chief Scientist (OCS). This grant, the second this year, brings the total awarded by OCS to Brainstorm for 2015 activities to approximately $1.8 million (approximately NIS7 million).
BCLI: 2.42 (-0.10)
BrainStorm CEO to Present at Two Investor Conferences in September
PR Newswire - Tue Sep 06, 6:30AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at two upcoming investor conferences: The Rodman & Renshaw 18th Annual Global Investment Conference, and the Maxim Inaugural Israel Day.
BCLI: 2.42 (-0.10)
BrainStorm's Valuation Doesn't Reflect Potential Value of NurOwn(R) Therapy
ACCESSWIRE - Tue Aug 16, 7:01AM CDT
CHARLOTTE, NC / ACCESSWIRE / August 16, 2016 / BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease (PD). The company's NurOwn® technology is based on the use of mesenchymal stem cells (MSCs) that are engineered ex vivo to express increased amount of neurotrophic factors (NTFs). The company has tested single-dose treatments of NurOwn in ALS patients in two Phase 1/2 clinical trials and most recently in a randomized, double-blind, placebo-controlled Phase 2 clinical trial.
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu Aug 11, 7:00AM CDT
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2016.
BCLI: 2.42 (-0.10)
BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London
PR Newswire - Tue May 17, 7:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting Thursday, May 19th, at the 11th World Stem Cells & Regenerative Medicine Congress in London, UK. Mr. Lebovits will moderate a round table session on Brainstorm's NurOwn® proprietary technology and its potential to introduce a groundbreaking treatment for Amyotrophic lateral sclerosis (ALS).
BCLI: 2.42 (-0.10)
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief Scientist
PR Newswire - Thu May 12, 7:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1,470,000 from Israel's Office of the Chief Scientist (OCS).
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
PR Newswire - Tue May 10, 8:26AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2016.
BCLI: 2.42 (-0.10)
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 238.41 (-0.26), AVXL: 2.61 (-0.03), ACOR: 27.07 (+0.71), BCLI: 2.42 (-0.10), FOLD: 7.94 (+0.05)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 91.82 (+0.13), BMRN: 97.57 (-0.38), VYGR: 13.86 (+0.15), RPTP: 8.99 (+0.02), KNMD: (), SGMO: 4.72 (+0.10), BCLI: 2.42 (-0.10), CUR: 0.31 (unch)
Jama Neurology Releases Highly Promising Data From ALS Clinical Trial Conducted By Hadassah Medical Organization Jerusalem And Brainstorm Cell Therapeutics
PR Newswire Europe - Mon Jan 11, 6:21PM CST
ALS Clinical Trial Results Provide Strong Indication That Stem Cell Treatment Inhibits ALS Disease Progression In 87% of Patients
BCLI: 2.42 (-0.10)
BrainStorm's NurOwn® for the Treatment of ALS Published in JAMA Neurology
PR Newswire - Mon Jan 11, 9:45AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016 edition of JAMA Neurology discussing the outcome of the first in man Phase 1/2 study and Phase 2 dose escalation study with NurOwn® in ALS. The data provide indication of clinically meaningful benefit as reflected by a slower rate of disease progression in the period post treatment. There was also a positive trend on two novel biomarkers, rate of decline of muscle volume and of compound motor axon potential (CMAPs). These are the first published clinical data with stem cells that have been induced under culture conditions to produce NTFs, with the potential to achieve a neuroprotective effect in ALS and modify the course of disease.
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn® Trial in ALS at Hadassah Medical Center
PR Newswire - Mon Jan 11, 6:30AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with Hadassah Medical Center in Jerusalem, Israel, to conduct the planned multi dose Phase 2 trial with NurOwn® in Amyotrophic Lateral Sclerosis (ALS).
BCLI: 2.42 (-0.10)
BrainStorm Reschedules Corporate Update Conference Call to January 11, 2016
PR Newswire - Thu Dec 10, 6:45AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call, originally scheduled for Wednesday, December 16, 2015 to Monday, January 11, 2016, due to longer than expected embargo on one of the important items to be discussed on the call. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer will provide an update to shareholders and discuss important company developments.
BCLI: 2.42 (-0.10)
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
PR Newswire - Mon Dec 07, 12:00AM CST
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Dr. Revital Geffen-Aricha, M.Sc., Ph.D., as Vice President of Research and Development. Dr. Geffen-Aricha will be based in Israel and report to Chaim Lebovits, President and Chief Executive Officer. She will be responsible for all research and development activities for BrainStorm.
BCLI: 2.42 (-0.10)
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Fri Dec 04, 8:00AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird"
in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives. ATHX: 1.97 (-0.01), IMUC: 0.12 (unch), BCLI: 2.42 (-0.10)
What's Driving the Price Movement - Research on HMN Financial, Metabolix, Brainstorm Cell Therapeutics and Milestone Scientific
ACCESSWIRE - Fri Dec 04, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / December 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: HMN Financial Inc. (NASDAQ: HMNF), Metabolix Inc. (NASDAQ: MBLX), Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) and Milestone Scientific Inc. (NYSE: MLSS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HMNF: 14.35 (unch), MLSS: 2.10 (+0.03), BCLI: 2.42 (-0.10), MBLX: 0.40 (+0.04)
BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
PR Newswire - Wed Dec 02, 8:10AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on Wednesday, December 16, 2015 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer will provide an update to shareholders and discuss important company developments.
BCLI: 2.42 (-0.10)
BrainStorm and Octane Biotech Announce Success in Cocoon(TM) Application Development Based on Customized Bioreactor for NurOwn® Stem Cells
PR Newswire - Tue Dec 01, 7:00AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian company that focuses on clinical systems for cell and tissue therapy, announced today that they have made significant progress toward the development of a novel bioreactor for industrial-scale manufacture of BrainStorm's NurOwn® neurotrophic-factor secreting mesenchymal stem cells. The companies have completed key development activities related to the customization of specific features of Octane's Cocoon(TM) instrumentation platform to enable efficient delivery of BrainStorm's NurOwn® stem cell therapy. The collaborative program has generated a NurOwn® therapy-specific cassette that is employed as a disposable cartridge within the standard Cocoon(TM) platform, along with a dedicated software program to deliver and track the NurOwn® process. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).
BCLI: 2.42 (-0.10)
BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist
PR Newswire - Mon Nov 30, 1:29AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant of approximately $735,000 from Israel's Office of the Chief Scientist (OCS). This grant, the second this year, brings the total awarded by OCS to Brainstorm for 2015 activities to approximately $1.8 million (approximately NIS7 million).
BCLI: 2.42 (-0.10)
(0)
(0)Scroll down for more posts ▼